First Time Loading...

Alpine Immune Sciences Inc
NASDAQ:ALPN

Watchlist Manager
Alpine Immune Sciences Inc Logo
Alpine Immune Sciences Inc
NASDAQ:ALPN
Watchlist
Price: 39.64 USD 2.56% Market Closed
Updated: Mar 29, 2024

Intrinsic Value

ALPN's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

Alpine Immune Sciences, Inc. is a development-stage pharmaceutical company, which engages in the discovery of protein-based immunotherapies to treat cancer and autoimmune and inflammatory diseases. [ Read More ]

The intrinsic value of one ALPN stock under the Base Case scenario is 4.78 USD. Compared to the current market price of 39.64 USD, Alpine Immune Sciences Inc is Overvalued by 88%.

Key Points:
ALPN Intrinsic Value
Base Case
4.78 USD
Overvaluation 88%
Intrinsic Value
Price
Base Case Scenario

Valuation Backtest
Alpine Immune Sciences Inc

Backtest ALPN Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling ALPN stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Financials

Balance Sheet Decomposition
Alpine Immune Sciences Inc

Current Assets 197.4m
Cash & Short-Term Investments 193.5m
Receivables 900k
Other Current Assets 3m
Non-Current Assets 43.1m
Long-Term Investments 33.5m
PP&E 9.2m
Other Non-Current Assets 400k
Current Liabilities 51.8m
Accounts Payable 3.1m
Accrued Liabilities 18.7m
Other Current Liabilities 30m
Non-Current Liabilities 27.1m
Other Non-Current Liabilities 27.1m
Efficiency

Earnings Waterfall
Alpine Immune Sciences Inc

Revenue
58.9m USD
Operating Expenses
-103.1m USD
Operating Income
-44.3m USD
Other Expenses
12.1m USD
Net Income
-32.2m USD

Free Cash Flow Analysis
Alpine Immune Sciences Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
What is Free Cash Flow?
Fundamental Scores

ALPN Profitability Score
Profitability Due Diligence

Alpine Immune Sciences Inc's profitability score is 26/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Years Revenue Growth
Exceptional 1-Year Revenue Growth
ROE is Increasing
ROIC is Increasing
26/100
Profitability
Score

Alpine Immune Sciences Inc's profitability score is 26/100. The higher the profitability score, the more profitable the company is.

ALPN Solvency Score
Solvency Due Diligence

Alpine Immune Sciences Inc's solvency score is 78/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Low D/E
Short-Term Solvency
Long-Term Solvency
78/100
Solvency
Score

Alpine Immune Sciences Inc's solvency score is 78/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

ALPN Price Targets Summary
Alpine Immune Sciences Inc

Wall Street analysts forecast ALPN stock price to drop over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ALPN is 34.24 USD with a low forecast of 29.29 USD and a high forecast of 46.2 USD.

Lowest
Price Target
29.29 USD
26% Downside
Average
Price Target
34.24 USD
14% Downside
Highest
Price Target
46.2 USD
17% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

ALPN Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

ALPN Price
Alpine Immune Sciences Inc

1M 1M
+13%
6M 6M
+246%
1Y 1Y
+391%
3Y 3Y
+296%
5Y 5Y
+478%
10Y 10Y
-34%
Annual Price Range
39.64
52w Low
6.84
52w High
41.6
Price Metrics
Average Annual Return 45.27%
Standard Deviation of Annual Returns 152.69%
Max Drawdown -72%
Shares Statistics
Market Capitalization 2.6B USD
Shares Outstanding 65 536 000
Percentage of Shares Shorted 11.01%

ALPN Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

Alpine Immune Sciences Inc Logo
Alpine Immune Sciences Inc

Country

United States of America

Industry

Biotechnology

Market Cap

2.6B USD

Dividend Yield

0%

Description

Alpine Immune Sciences, Inc. is a development-stage pharmaceutical company, which engages in the discovery of protein-based immunotherapies to treat cancer and autoimmune and inflammatory diseases. The company is headquartered in Seattle, Washington and currently employs 85 full-time employees. The company went IPO on 2015-06-17. The firm is focused on discovering and developing protein-based immunotherapies to treat cancer and autoimmune and inflammatory diseases. The firm's scientific platform uses a directed evolution process to convert native immune system proteins from the immunoglobulin super family (IgSF) into multi-targeted therapeutics capable of modulating the human immune system. Its product candidates include ALPN-101, ALPN-202 and ALPN-303. ALPN-101 is a dual inducible T cell costimulator (ICOS) and cluster of differentiation 28 (CD28) antagonist intended for the treatment of autoimmune and inflammatory diseases. Its oncology program is ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor intended for the treatment of cancer. ALPN-303 is a dual B-cell cytokine antagonist for the treatment of B-cell mediated diseases.

Contact

WASHINGTON
Seattle
188 East Blaine St., Suite 200
+12067884545.0
https://www.alpineimmunesciences.com/

IPO

2015-06-17

Employees

85

Officers

Executive Chairman & CEO
Dr. Mitchell H. Gold M.D.
President and Head of Research & Development
Dr. Stanford Peng M.D., Ph.D.
Senior VP, CFO, Treasurer & Secretary
Mr. Paul Rickey
Chief Technology Officer
Ms. M. Christina Yi
Head of IR & Corporate Communications
Temre Johnson
Chief Business Officer
Dr. Remy Durand Ph.D.
Show More
Chief Medical Officer
Dr. Wolfgang Dummer M.D., Ph.D.
Show Less

See Also

Discover More
What is the Intrinsic Value of one ALPN stock?

The intrinsic value of one ALPN stock under the Base Case scenario is 4.78 USD.

Is ALPN stock undervalued or overvalued?

Compared to the current market price of 39.64 USD, Alpine Immune Sciences Inc is Overvalued by 88%.